Hepta and collaborators announced a liquid biopsy technology and a landmark partnership to map the biology of metabolic dysfunction‑associated steatohepatitis (MASH). Hamed Amini described a program to integrate circulating biomarkers with multi‑omic mapping to enable earlier, noninvasive diagnosis of MASH and patient stratification for trials. The collaboration aims to create a blood‑based map of disease biology that can be used to triage patients into therapeutic studies and monitor response. Hepta framed the effort as a translational bridge linking discovery assays to clinical trial enrollment and regulatory evidence generation.